First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. 2004

Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. thadhani.r@mgh.harvard.edu

An imbalance of pro- and antiangiogenic factors may lead to preeclampsia (PE). In this prospective nested case-control study, we investigated whether first trimester serum levels of placental growth factor (PlGF), a potent angiogenic factor, and its soluble inhibitor, soluble fms-like tyrosine kinase 1 (sFlt1), distinguished women who developed PE (n = 40) from those who developed gestational hypertension (n = 40), delivered a small for gestational age (SGA) newborn (n = 40), or completed a full term normal pregnancy (n = 80). Compared with controls, serum PlGF levels were lower among women who developed PE (23 +/- 24 pg/ml vs. 63 +/- 145 pg/ml; P < 0.01) or gestational hypertension (27 +/- 19 pg/ml; P = 0.03), or who delivered a SGA newborn (21 +/- 16 pg/ml; P < 0.01). In contrast, serum sFlt1 levels did not markedly differ between the groups: PE, 1048 +/- 657 pg/ml; gestational hypertension, 942 +/- 437 pg/ml; SGA newborns, 1011 +/- 479 pg/ml; and normal controls, 973 +/- 490 pg/ml. Multivariable analysis adjusting for potential confounders and serum sFlt1 levels demonstrated a 3.7-fold (95% confidence interval, 1.2-12.5) increase in risk for PE for every log unit decrease in serum levels of PlGF compared with controls. Analyses for gestational hypertension and SGA were not significant. Examined in tertiles, the risk for PE was increased 28.7-fold (95% confidence interval, 2.3-351.0) in the third (<12 pg/ml) compared with the first (>39 pg/ml) PlGF tertile. First trimester serum levels of PlGF and sFlt1 may identify women at high risk for PE.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007236 Infant, Small for Gestational Age An infant having a birth weight lower than expected for its gestational age.
D011225 Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease. Toxemias, Pregnancy,EPH Complex,EPH Gestosis,EPH Toxemias,Edema-Proteinuria-Hypertension Gestosis,Gestosis, EPH,Hypertension-Edema-Proteinuria Gestosis,Preeclampsia,Preeclampsia Eclampsia 1,Pregnancy Toxemias,Proteinuria-Edema-Hypertension Gestosis,Toxemia Of Pregnancy,1, Preeclampsia Eclampsia,1s, Preeclampsia Eclampsia,EPH Toxemia,Eclampsia 1, Preeclampsia,Eclampsia 1s, Preeclampsia,Edema Proteinuria Hypertension Gestosis,Gestosis, Edema-Proteinuria-Hypertension,Gestosis, Hypertension-Edema-Proteinuria,Gestosis, Proteinuria-Edema-Hypertension,Hypertension Edema Proteinuria Gestosis,Of Pregnancies, Toxemia,Of Pregnancy, Toxemia,Pre Eclampsia,Preeclampsia Eclampsia 1s,Pregnancies, Toxemia Of,Pregnancy Toxemia,Pregnancy, Toxemia Of,Proteinuria Edema Hypertension Gestosis,Toxemia Of Pregnancies,Toxemia, EPH,Toxemia, Pregnancy,Toxemias, EPH
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011249 Pregnancy Complications, Cardiovascular The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS. Cardiovascular Pregnancy Complications,Complications, Cardiovascular Pregnancy,Pregnancy, Cardiovascular Complications,Cardiovascular Pregnancy Complication,Complication, Cardiovascular Pregnancy,Pregnancies, Cardiovascular Complications,Pregnancy Complication, Cardiovascular
D011257 Pregnancy Proteins Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.) Placental Proteins,Proteins, Placental,Proteins, Pregnancy
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females

Related Publications

Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
September 2013, Journal of perinatology : official journal of the California Perinatal Association,
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
May 2020, Hypertension in pregnancy,
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
October 2019, Journal of gynecology obstetrics and human reproduction,
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
April 2013, Clinical chemistry and laboratory medicine,
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
October 2012, Hypertension (Dallas, Tex. : 1979),
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
October 2010, PloS one,
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
June 2007, Obstetrics and gynecology,
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
January 2023, Current hypertension reviews,
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
January 2010, Acta obstetricia et gynecologica Scandinavica,
Ravi Thadhani, and Walter P Mutter, and Myles Wolf, and Richard J Levine, and Robert N Taylor, and Vikas P Sukhatme, and Jeffrey Ecker, and S Ananth Karumanchi
October 2020, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC,
Copied contents to your clipboard!